Trial Condition(s):
Secondary Peritonitis, Abscess, Intra-Abdominal
Moxifloxacin i.v. in the treatment of Complicated Intra-Abdominal Infection (cIAI)
Bayer Identifier:
14537
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from a cIAI and take at least one dose of Moxifloxacin infusion.The primary objective is to define the types of cIAI infections that require Moxifloxacin i.v. therapy in China.
Inclusion Criteria
- Patients at least 18 years of age with a diagnosis of cIAI treated with Moxifloxacin infusion with/without sequential tablet treatment can be included into the study. The local Moxifloxacin product information must be considered.
Exclusion Criteria
- Contraindications stated in the local Moxifloxacin product information. Warnings and precautions, stated in the local Moxifloxacin product information must be considered as potential exclusion criteria.
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Many locations, China | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Clinical effectiveness and safety study of Moxifloxacin i.v. in the treatment of Complicated Intra-Abdominal Infection (cIAI)
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Types of cIAI infectionsTimeframe: Day 1
Secondary Outcome
- Cure rateTimeframe: 5-14 days
- Clinical signs and symptomsTimeframe: 5-14 days
- Duration until improvement and cureTimeframe: 5-14 days
- Adverse event collectionTimeframe: 5-14 days
Additional Information
Copyright © Bayer
Powered by
